Instead of making the “o” in Shutterstock look like a viewfinder, now it has “ripples” coming off the top and bottom to ...

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the ...

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. However, Iovance's full-year ...

Iovance Biotherapeutics (NASDAQ: IOVA) just might be the right kind of biotech stock. The company has already achieved success. Could it even be a millionaire-maker? To appreciate Iovance's ...

Iovance has a huge opportunity with its tumor-infiltrating lymphocyte (TIL) therapies. However, there are several drawbacks to investing in the stock right now. Even if Iovance isn't a millionaire ...

Newly commercial stage biopharma Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has delivered a couple of quarterly earnings beats since we last put in the spotlight in July of this year. The company ...

While that level of success is only obvious in hindsight, Iovance Biotherapeutics (NASDAQ: IOVA) is an emerging industry leader with significant potential. The company's tumor-infiltrating ...

Iovance Biotherapeutics ( (IOVA)) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its investors. Iovance Biotherapeutics, Inc. is a ...

Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials ...